Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalating Phase I, Healthy Subjects Study of Intravenous OPN‐305, a Humanized Anti‐TLR2 Antibody

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 5, 2013-11 ,pp. : 593-600

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I trial assessing the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of single‐dose Auron Misheil therapy in healthy male subjects

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 38, Iss. 1, 2013-02 ,pp. : 3-11

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I trial assessing the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of single‐dose Auron Misheil therapy in healthy male subjects

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 269-4727, Iss. 1, 2013-02 ,pp. : 3-11

John Wiley & Sons Inc

Access to resources Recommend Favorite

Single‐dose evaluation of safety, tolerability and pharmacokinetics of newly formulated hydromorphone immediate‐release and hydrophilic matrix extended‐release tablets in healthy Japanese subjects without co‐administration of an opioid antagonist

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 9, 2015-09 ,pp. : 975-984

John Wiley & Sons Inc

Access to resources Recommend Favorite

Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study

By Keller G.A.   Czerniuk P.   Bertuola R.   de Mena F.   Simoni M.V.   Assefi A.R.   Di Girolamo G.  

Current Medical Research and Opinion, Vol. 27, Iss. 11, 2011-11 ,pp. : 2203-2211

Informa Healthcare

Access to resources Recommend Favorite